Latest from RCCA

Terrill Jordan, president and CEO of Regional Cancer Care Associates, discusses RCCA’s efforts to further the fee-for-value model in oncology and make drugs more readily available to patients with cancer.

Ralph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.

Andrew Jennis, MD a hematologist/oncologist at Hackensack Meridian Health, who specializes in the diagnosis and treatment of digestive cancers, discusses the Centers for Medicare & Medicaid Services’ Oncology Care Model, a value model in which there is the opportunity for shared savings for both oncologists and CMS, so long as oncology care is administered in a cost-efficient manner.

Lani Alison, BCN, MS, HCQ, PCMH, CCE, vice president of clinical affairs at Regional Cancer Care Associates (RCCA), discusses future plans to develop an oft-overlooked area of oncology–survivorship/palliative care.

Kathleen Toomey, MD, who specializes in hematology and medical oncology and practices at the Steeplechase Cancer Center, discusses the results of the TAILORx trial, which reported that some patients with early-stage breast cancer can avoid chemotherapy.

Joel Silver, MD, a medical oncologist and a member of the board of directors of Regional Cancer Care Associates, discusses the progress being made in the treatment of hematological cancers, especially in multiple myeloma.

Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.

Seth Berk, MD, section chief of gastrointestinal hematology/oncology at Virtua Memorial Hospital, discusses the use of immunotherapy in colon cancer.